title: A rare primary liver tumor that responded to sorafenib.
authors.affiliation: Department of Gastroenterology and Hepatology, Niigata Prefectural Shibata Hospital, Shibata City, Niigata, Japan; Department of Gastroenterology and Hepatology, Graduate School of Medical and Dental Science, Niigata University, Niigata City, Niigata, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Seino
authors.affiliation: Department of Gastroenterology and Hepatology, Graduate School of Medical and Dental Science, Niigata University, Niigata City, Niigata, Japan.
authors.forename: Atsunori
authors.initials: A
authors.lastname: Tsuchiya
authors.affiliation: Department of Gastroenterology and Hepatology, Niigata Prefectural Shibata Hospital, Shibata City, Niigata, Japan.
authors.forename: Masashi
authors.initials: M
authors.lastname: Watanabe
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D018281:Cholangiocarcinoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D039621:Eukaryotic Initiation Factor-3 / Q000378:metabolism; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; C105988:EIF3A protein, human; D039621:Eukaryotic Initiation Factor-3; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib; D019009:Proto-Oncogene Proteins c-kit